New hope for advanced cancer: first human trial of ALK201 begins
Disease control
Recruiting now
This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC